Characteristics of patients with pSS and healthy controls
| Characteristics (n=31) | |||
|---|---|---|---|
| Age, mean (range) | 46.2 (25–79) | ||
| Sex | Female (n=30), male (n=1) | ||
| Ethnicity, n (%) | Caucasian (n=31, 100%) | ||
| pSS subgroups | Glandular (n=15) | Extraglandular (n=16) | |
| Age, mean (range), ns. | 44.6 (29–79) | 47.75 (25–79) | |
| Dryness of the mouth (VAS 1–10) | 6.3 | 6 | |
| Dryness of the eyes (VAS 1–10) | 6.25 | 6.15 | |
| Extraglandular manifestations: | |||
| Arthritis | – | 5 | |
| Myositis | – | 3 | |
| Leukocytoclastic vasculitis | – | 4 | |
| Polyneuropathy | – | 4 | |
| Interstitial lung disease | – | 3 | |
| Pulmonary aterial hypertension | – | 1 | |
| Interstitial nephritis | – | 1 | |
| Medication: | |||
| Hydroxychloroquine, n (mean) | 2 (200 mg) | 6 (300 mg) | |
| Prednisolone, n (mean) | 7 (5.8 mg) | 1 (2 mg) | |
| Azathioprine, n (mean) | 1 (75 mg) | 0 | |
| Cyclophosphamide, n (mean) | 3 (1 g/month) | 0 | |
| No therapy, n | 6 | 8 | |
| Autoantibodies: | |||
| ANA titre >1/160, (mean) | 15 (1:1540) | 16 (1:1950) | |
| Anti-SSA | 12 | 16 | |
| Anti-SSB | 4 | 8 | |
| Anti-SSA positive+Anti-SSB positive | 4 | 8 | |
| Glandular vs extraglandular manifestation | |||
| Median, significance p<0.05, MWU | |||
| ANA titre | 640 | 1280 | ns. (p=0.61) |
| RF IgA U/mL | 17 | 100 | ns. (p=0.12) |
| RF IgM U/mL | 14 | 67 | ns. (p=0.5) |
| Gammaglobulines, g/L | 9.9 | 18.14 | **(p=0.007) |
| Haemoglobin g/dL | 13.2 | 13.2 | ns. (p=0.77) |
| Leucocytes/nL | 5.8 | 5.3 | ns. (p=0.82) |
| Neutrophils/nL | 4 | 3.7 | ns. (p=0.46) |
| Lymphocytes/nL | 1.3 | 1.1 | ns. (p=0.45) |
| Thrombocytes/nL | 244 | 235 | ns. (p=0.74) |
| C reactive protein mg/L | 1.6 | 1.1 | ns. (p=0.92) |
| Complement C3, mg/L | 1035 | 1010 | ns. (p=0.8) |
| Complement C4, mg/L | 210 | 150 | ns. (p=0.08) |
ANA, antinuclear antibody; CNS, central nervous system; egl., extraglandular; gl, glandular; MWU, Mann-Whitney U Test; ns, not significant; *p ≤0.05; **p <0.01. PNS, peripheral nervous system; pSS, primary Sjögren's syndrome; RF, rheumatoid factor; VAS, visual analogue scale.